Sprint Bioscience AB (OSTO:SPRINT) FCF Margin %: 0.00% (As of Mar. 2026)

What is Sprint Bioscience AB FCF Margin %?

Sprint Bioscience AB OSTO:SPRINT -4.92% 32 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 954 Biotechnology companies, Sprint Bioscience AB ranks better than 96.23% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Sprint Bioscience AB's Free Cash Flow for the three months ended in Mar. 2026 was kr-19.3 Mil. Sprint Bioscience AB's Revenue for the three months ended in Mar. 2026 was kr0.0 Mil. Therefore, Sprint Bioscience AB's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Sprint Bioscience AB's current FCF Yield % is 16.45%.

The historical rank and industry rank for Sprint Bioscience AB's FCF Margin % or its related term are showing as below:

OSTO:SPRINT' s FCF Margin % Range Over the Past 10 Years
Min: -190.84 Med: -83.77 Max: 49.91
Current: 46.05

During the past 13 years, the highest FCF Margin % of Sprint Bioscience AB was 49.91%. The lowest was -190.84%. And the median was -83.77%.

OSTO:SPRINT's FCF Margin % is ranked better than
96.23% of 954 companies
in the Biotechnology industry
Industry Median: -84.535 vs OSTO:SPRINT: 46.05

Sprint Bioscience AB FCF Margin % Related Terms

Sprint Bioscience AB FCF Margin % Historical Data

* Premium members only.

The historical data trend for Sprint Bioscience AB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sprint Bioscience AB FCF Margin % Chart

Sprint Bioscience AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

-121.96

0.00

40.44

-37.56

49.91

Sprint Bioscience AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															-39.34	-87.56	-265.12	86.51	0.00

OSTO:SPRINT vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Sprint Bioscience AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sprint Bioscience AB FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Sprint Bioscience AB's FCF Margin % falls into.

Save Embed

32GF Score

Sprint Bioscience AB OSTO:SPRINT

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Sprint Bioscience AB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Sprint Bioscience AB's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	83.438	/	167.168
	=	49.91 %

Sprint Bioscience AB's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-19.291	/	0
	=	%

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 0.00% mean?

Sprint Bioscience AB (OSTO:SPRINT) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sprint Bioscience AB and its competitors. According to the industry distribution chart, Sprint Bioscience AB ranks #36 out of 954 companies in the Biotechnology industry, placing it in the top 3.8%.

Is Sprint Bioscience AB's FCF Margin % too high?

Sprint Bioscience AB's current FCF Margin % is 0.00%. Based on the distribution chart, Sprint Bioscience AB ranks #36 out of 954 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Sprint Bioscience AB's FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #36 out of 954 companies for FCF Margin %. This places Sprint Bioscience AB in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Sprint Bioscience AB and its competitors. Sprint Bioscience AB's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Sprint Bioscience AB stock overvalued right now?

Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current FCF Margin % is 0.00%. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?

Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued. The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18. GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.

Key valuation signals for OSTO:SPRINT:

FCF Margin %: 0.00%
GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
GF Score™: 32/100 with 4 warning signs

No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sprint Bioscience AB Business Description

Industry Healthcare Biotechnology

Comparable Companies OSTO:CLBIO OSTO:IVACC OSTO:ALZCUR OSTO:ACE OSTO:CANTA XSAT:CESSA OSTO:IMMU OSTO:ONCO OSTO:FLUO OSTO:ISOFOL VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 5JA1:Germany

Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57

Website https://www.sprintbioscience.com

Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.

32GF Score

Get the complete analysis for OSTO:SPRINT

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr4.06

Price

kr2.18

GF Value

View OSTO:SPRINT Analysis

See FCF Margin % data for all stocks →